ODYY - Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health Inc. (ODYY) as Next-stage Trials are Readied
- Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments
- The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly on members of the military
- Odyssey’s technology combines a synthetic medication with a specially designed application device that helps the medication cross the blood-brain barrier for immediate responsiveness following a mild traumatic brain injury (“mTBI”)
- Medication for concussion treatment remains an unmet need and Odyssey is aiming to be a first-mover in the healthcare sector
The National Council on Aging sponsors its Falls Prevention Week timed, not ironically, during the fall of each year, using its national health campaign to combat the leading cause of fatal and non-fatal injuries among older adults.
One message of the council’s awareness campaign is the importance of recognizing that after an old person is helped back up, the fall victim may be able to resume walking, but there is still a significant risk of...
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at http://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.